Tandem Diabetes (TNDM) Care announced that the United States Food and Drug Administration, FDA, has cleared Control-IQ+ automated insulin delivery, AID, technology for use in pregnancy complicated by type 1 diabetes mellitus. Control-IQ+ powers both insulin delivery systems from Tandem – the t:slim X2 and Tandem Mobi, the first and only commercially available AID systems cleared for use during pregnancy in the United States.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $45 from $36 at Rothschild & Co Redburn
- Tandem Diabetes price target raised to $28 from $25 at TD Cowen
- Leveraging Rx Channel Shift and Mobi Tubeless Launch to Drive Sustainable Growth at Tandem Diabetes Care
- Citi adds ‘upside 90-day catalyst watch’ on Tandem Diabetes
- Micron downgraded, Five Below upgraded: Wall Street’s top analyst calls